International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 62

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in *Cumulative List No. 12, 2007* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 62

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la *Liste récapitulative No. 12, 2007* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 62

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en *Cumulative List No. 12, 2007* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*


adarotenum

adarotene — (2*E*)-3-[3'-(adamantan-1-yl)-4'-hydroxy-1,1'-biphenyl-4-yl]prop-2-enoic acid

adarotène — acide (2*E*)-3-[4'-hydroxy-3'-(adamantan-1-yl)biphényl-4-yl]prop-2-énoïque

adaroteno — ácido 3-[3'-(adamantan-1-il)-4'-hidroxi-1,1'-bifenil-4-il]prop-2-enoico

$C_{25}H_{26}O_3$




afamelanotidum

afamelanotide — *N*-acetyl-L-serinyl-L-tyrosyl-L-seryl-(2*S*)-2-aminohexanoyl-L-glutamyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophanylglycyl-L-lysyl-L-prolyl-L-valinamide

afamélanotide — *N*-acétyl-L-sérinyl-L-tyrosyl-L-séryl-(2*S*)-2-aminohexanoyl-L-glutamyl-L-histidyl-D-phénylalanyl-L-arginyl-L-tryptophanylglycyl-L-lysyl-L-prolyl-L-valinamide

afamelanotida — *N*-acetil-L-serinil-L-tirosil-L-seril-(2*S*)-2-aminohexanoil-L-glutamil-L-histidil-D-fenilalanil-L-arginil-L-triptofanilglicil-L-lisil-L-prolil-L-valinamida

$C_{78}H_{111}N_{21}O_{19}$




alisporivirum

alisporivir — [8-(*N*-methyl-D-alanine),9-(*N*-ethyl-L-valine)]cyclosporine

alisporivir — [8-(*N*-méthyl-D-alanine),9-(*N*-éthyl-L-valine)]cyclosporine

alisporivir — [8-(*N*-metil-D-alanina),9-(*N*-etil-L-valina)]ciclosporina

$C_{63}H_{113}N_{11}O_{12}$




amenamevirum

amenamevir — *N*-(2,6-dimethylphenyl)-*N*-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl]amino}-2-oxoethyl)-1,1-dioxothiane-4-carboxamide

aménamévir — *N*-(2,6-diméthylphényl)-*N*-(2-{[4-(1,2,4-oxadiazol-3-yl)phényl]amino}-2-oxoéthyl)-1,1-dioxothiane-4-carboxamide

amenamevir — *N*-(2,6-dimetilfenil)-*N*-(2-{[4-(1,2,4-oxadiazol-3-il)fenil]amino}-2-oxoetil)-1,1-dioxotiano-4-carboxamida

$C_{24}H_{26}N_4O_5S$




atigliflozinum

atigliflozin — 2-[(4-methoxyphenyl)methyl]thiophen-3-yl β-D-glucopyranoside

atigliflozine — β-D-glucopyranoside de 2-[(4-méthoxyphényl)méthyl]thiophén-3-yle

atigliflozina — β-D-glucopiranósido de 2-[(4-metoxifenil)metil]-3-tienilo

$C_{18}H_{22}O_7S$




balapiravirum

balapiravir — 4'-*C*-azido-2',3',5'-tris[*O*-(2-methylpropanoyl)]cytidine

balapiravir — 4'-*C*-azido-2',3',5'-tris[*O*-(2-méthylpropanoyl)]cytidine

balapiravir — 4'-*C*-azido-2',3',5'-tris[*O*-(2-metilpropanoil)]citidina

$C_{21}H_{30}N_6O_8$




beloranibum

beloranib — (3*R*,4*S*,5*S*,6*R*)-5-methoxy-4-[(2*R*,3*R*)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl (2*E*)-3-{4-[2-(dimethylamino)ethoxy]phenyl}prop-2-enoate

béloranib — (2*E*)-3-{4-[2-(diméthylamino)éthoxy]phényl}prop-2-énoate de (3*R*,4*S*,5*S*,6*R*)-5-méthoxy-4-[(2*R*,3*R*)-2-méthyl-3-(3-méthylbut-2-én-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yle

beloranib — (2*E*)-3-{4-[2-(dimetilamino)etoxi]fenil}prop-2-enoato de (3*R*,4*S*,5*S*,6*R*)- 4-[(2*R*,3*R*)-2-metil-3-(3-metilbut-2-en-1-il)oxiran-2-il]-5-metoxi-1-oxaspiro[2.5]octan-6-ilo

$C_{29}H_{41}NO_6$



blinatumomabum #

blinatumomab — immunoglobulin scFv-scFv, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)]/anti-[*Homo sapiens* CD3 epsilon (CD3E, Leu-4)] *Mus musculus* monoclonal antibody bispecific single chain;
Mus musculus scFv anti-CD19 [V-KAPPA (IGKV3-4-IGKJ1*01) [10.3.9] (1-111) -tris(tetraglycyl-seryl) -VH (IGHV1-54-(IGHD)-IGHJ4*01, S123>T) [8.8.17] (127-250)] -tetraglycyl-seryl -*Mus musculus* scFv anti-CD3E [VH (IGHV1-4-(IGHD)-IGHJ2*01) [8.8.12] (256-374) -valyl-glutamyl-tetrakis(diglycyl-seryl)-diglycyl-valyl-aspartyl -V-KAPPA (IGKV4-59-IGKJ5*01) [5.3.9] (393-498)] -hexahistidine

blinatumomab

immunoglobuline scFv-scFv, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)]/anti-[*Homo sapiens* CD3 epsilon (CD3E, Leu-4)] *Mus musculus* anticorps monoclonal bispécifique à chaîne unique;
Mus musculus scFv anti-CD19 [V-KAPPA (IGKV3-4-IGKJ1*01) [10.3.9] (1-111) -tris(tétraglycyl-séryl) -VH (IGHV1-54-(IGHD)-IGHJ4*01, S123>T [8.8.17] (127-250) -tétraglycyl-séryl -*Mus musculus* scFv anti-CD3E [VH (IGHV1-4-(IGHD)-IGHJ2*01 [8.8.12] (256-374) -valyl-glutamyl-tétrakis(diglycyl-seryl)-diglycyl-valyl-aspartyl -V-KAPPA (IGKV4-59-IGKJ5*01 [5.3.9] (393-498)] – hexahistidine

blinatumomab

inmunoglobulina scFv-scFv, anti-[*Homo sapiens* CD19 (antígeno de superficie B4 de los linfocitos B, Leu-12)]/anti-[*Homo sapiens* CD3 epsilon (CD3E, Leu-4)] anticuerpo monoclonal biespecífico de *Mus musculus* de cadena única;
Mus musculus scFv anti-CD19 [V-KAPPA (IGKV3-4-IGKJ1*01) [10.3.9] (1-111) -tris(tetraglicil-seril) -VH (IGHV1-54-(IGHD)-IGHJ4*01, S123>T [8.8.17] (127-250) -tetraglicil-seril -*Mus musculus* scFv anti-CD3E [VH (IGHV1-4-(IGHD)-IGHJ2*01 [8.8.12] (256-374) -valil-glutamil-tetrakis(diglicil-seril)-diglicil-valil-aspartil -V-KAPPA (IGKV4-59-IGKJ5*01 [5.3.9] (393-498)] –hexahistidina

$C_{2367}H_{3577}N_{649}O_{772}S_{19}$

```
DIQLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDSYLNWY QQIPGQPPKL  50
LIYDASNLVS GIPPRFSGSG SGTDFTLNIH PVEKVDAATY HCQQSTEDPW 100
TFGGGTKLEI KGGGGSGGGG SGGGGSQVQL QQSGAELVRP GSSVKISCKA 150
SGYAFSSYWM NWVKQRPGQG LEWIGQIWPG DGDTNYNGKF KGKATLTADE 200
SSSTAYMQLS SLASEDSAVY FCARRETTTV GRYYYAMDYW GQGTTVTVSS 250
GGGGSDIKLQ QSGAELARPG ASVKMSCKTS GYTFTRYTMH WVKQRPGQGL 300
EWIGYINPSR GYTNYNQKFK DKATLTTDKS SSTAYMQLSS LTSEDSAVYY 350
CARYYDDHYC LDYWGQGTTL TVSSVEGGSG GSGGSGGSGG VDDIQLTQSP 400
AIMSASPGEK VTMTCRASSS VSYMNWYQQK SGTSPKRWIY DTSKVASGVP 450
YRFSGSGSGT SYSLTISSME AEDAATYYCQ QWSSNPLTFG AGTKLELKHH 500
HHHH                                                    504
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
23-92 148-222 277-351 415-479

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
307 (but Pro in 308)

canosimibum

canosimibe

N-(1-deoxy-D-glucitol-1-*C*-yl)-*N*'-[(4-{(2S,3R))-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl}phenyl)methyl]dodecanediamide


canosimibe

N-(1-déoxy-D-glucitol-1-*C*-yl)-*N*'-[(4-{(2*S*,3*R*))-3-[(3S)-3-(4-fluorophényl)-3-hydroxypropyl]-2-(4-méthoxyphényl)-4-oxoazétidin-1-yl}phényl)méthyl]dodécanediamide

canosimiba

N-(1-desoxi-D-glucitol-1-*C*-il)-*N*'-[(4-{(2*S*,3*R*))-3-[(3S)-3-(4-fluorofenil)-3-hidroxipropil]-2-(4-metoxifenil)-4-oxoazetidin-1-il}fenil)metil]dodecanediamida

$C_{44}H_{60}FN_3O_{10}$



cixutumumabum #

cixutumumab

immunoglobulin G1-lambda, anti-[*Homo sapiens* insulin-like growth factor I receptor (IGF-1R, CD221)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-460) [*Homo sapiens* VH (IGHV1-69*06 (99.00%) -(IGHD)-IGHJ6*01) [8.8.23] (1-130) -IGHG1*03, R120>K (131-460)], (233-213')-disulfide with lambda light chain (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-19*01 (92.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01, T124>A (109'-214')]; (239-239":242-242")-bisdisulfide dimer

cixutumumab

immunoglobuline G1-lambda, anti-[*Homo sapiens* récepteur du facteur de croissance analogue à l'insuline-1 (IGF-1R, CD221)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-460) [*Homo sapiens* VH (IGHV1-69*06 (99.00%) -(IGHD)-IGHJ6*01) [8.8.23] (1-130) -IGHG1*03, R120>K (131-460)], (233-213')-disulfure avec la chaîne légère lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-19 (92.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01, T124>A (109'-214')]; dimère (239-239":242-242")-bisdisulfure

cixutumumab

inmunoglobulina G1-lambda, anti-[receptor del factor de crecimiento insulínico-tipo 1 de *Homo sapiens* (conocido como: IGF-1R, CD221)], *Homo sapiens* anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-460) [VH (IGHV1-69*06 (99.00%) -(IGHD)-IGHJ6*01) [8.8.23] (1-130) -IGHG1*03, R120>K (131-460)], (233-213')-disulfuro con la cadena ligera lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-19 (92.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01, T124>A (109'-214')]; dímero (239-239":242-242")-bisdisulfuro

$C_{6500}H_{10052}N_{1724}O_{2036}S_{44}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWVRQA PGQGLEWMGG  50
IIPIFGTANY AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARAP 100
LRFLEWSTQD HYYYYYMDVW GKGTTVTVSS ASTKGPSVFP LAPSSKSTSG 150
GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT 200
VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG 250
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA 300
KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS 350
KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP 400
ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT 450
QKSLSLSPGK                                            460
```

Light chain / Chaîne légère / Cadena ligera

```
SSELTQDPAV SVALGQTVRI TCQGDSLRSY YATWYQQKPG QAPILVIYGE  50
NKRPSGIPDR FSGSSSGNTA SLTITGAQAE DEADYYCKSR DGSGQHLVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP AECS                                       214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 157-213 274-334 380-438
22"-96" 157"-213" 274"-334" 380"-438"
Intra-L 22'-87' 136'-195'
22'"-87'" 136'"-195'"
Inter-H-L 233-213' 233"-213'"
Inter-H-H 239-239" 242-242"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
310, 310"


coleneuramidum

coleneuramide — 5-acetamido-*N*-(5α-cholestan-3α-yl)-3,5-dideoxy-2-*O*-methyl-D-*glycero*-α-D-*galacto*-non-2-ulopyranosonamide

coléneuramide — 5-acétamido-*N*-(5α-cholestan-3α-yl)-3,5-didéoxy-2-*O*-méthyl-D-*glycéro*-α-D-*galacto*-non-2-ulopyranosonamide

coleneuramida — 5-acetamido-*N*-(5α-colestan-3α-il)-3,5-didesoxi-2-*O*-metil-D-*glicero*-α-D-*galacto*-non-2-ulopiranosonamida

$C_{39}H_{68}N_2O_8$




cositecanum

ositecan — (4*S*)-4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-3,14(4*H*)-dione

cositécan — (4*S*)-4-éthyl-4-hydroxy-11-[2-(triméthylsilyl)éthyl]-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléine-3,14(4*H*)-dione

ositecán — (4*S*)-4-etil-4-hidroxi-11-[2-(trimetilsilil)etil]-1,12-dihidro-14*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolina-3,14(4*H*)-diona

$C_{25}H_{28}N_2O_4Si$




cutamesinum

cutamesine — 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine

cutamésine — 1-[2-(3,4-diméthoxyphényl)éthyl]-4-(3-phénylpropyl)pipérazine

cutamesina — 1-[2-(3,4-dimetoxifenil)etil]-4-(3-fenilpropil)piperazina

$C_{23}H_{32}N_2O_2$



davunetidum

davunetide	human activity-dependent neuroprotector (ADNP)-(354-361)-peptide
davunétide	neuroprotecteur activité-dépendant humain (ADNP)-(354-361)-peptide
davunetida	neuroprotector humano dependiente de actividad (ADNP)-péptido-(354-361)


$C_{36}H_{60}N_{10}O_{12}$

H–Asn–Ala–Pro–Val–Ser–Ile–Pro–Gln–OH

delafloxacinum

delafloxacin	1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
délafloxacine	acide 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazétidin-1-yl)-4-oxo-1,4-dihydroquinoléine-3-carboxylique
delafloxacino	ácido 1-(6-amino-3,5-difluoropiridin-2-il)-8-cloro-6-fluoro-7-(3-hidroxiazetidin-1-il)-4-oxo-1,4-dihidroquinolina-3-carboxílico

$C_{18}H_{12}ClF_3N_4O_4$



dirucotidum

dirucotide	human myelin basic protein (myelin membrane encephalitogenic protein)-(216-232)-peptide L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine

dirucotide

protéine basique de la myéline humaine (protéine encéphalitogénique de la membrane de la myéline)-(216-232)-peptide
L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phénylalanyl-L-phénylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-thréonyl-L-prolyl-L-arginyl-L-thréonine

dirucotida

proteina básica de la mielina humana (proteina encefalitogénica de la membrana de mielina)-péptido (216-232)
L-α-aspartil-L-α-glutamil-L-asparaginil-L-prolil-L-valil-L-valil-L-histidil-L-fenilalanil-L-fenilalanil-L-lisil-L-asparaginil-L-isoleucil-L-valil-L-treonil-L-prolil-L-arginil-L-treonina

$C_{92}H_{141}N_{25}O_{26}$

H−Asp−Glu−Asn−Pro−Val−Val−His−Phe−Phe−
Lys−Asn−Ile−Val−Thr−Pro−Arg−Thr−OH
10 17

dutogliptinum

dutogliptin

[(2*R*)-1-{[(3*R*)-pyrrolidin-3-ylamino]acetyl}pyrrolidin-2-yl]boronic acid


dutogliptine

acide [(2*R*)-1-{[(3*R*)-pyrrolidin-3-ylamino]acétyl}pyrrolidin-2-yl]boronique

dutogliptina

àcido [(2*R*)-1-{[(3*R*)-pirrolidin-3-ilamino]acetil}pirrolidin-2-il]borónico

$C_{10}H_{20}BN_3O_3$



elacytarabinum

elacytarabine

4-amino-1-{5-*O*-[(9*E*)-octadec-9-enoyl]-β-D-arabinofuranosyl}=pyrimidin-2(1*H*)-one


élacytarabine

4-amino-1-[5-*O*-[(9*E*)-octadéc-9-énoyl]-β-D-arabinofuranosyl]=pyrimidin-2(1*H*)-one

elacitarabina

4-amino-1-{5-*O*-[(9*E*)-octadec-9-enoil]-β-D-arabinofuranosil}pirimidin-2(1*H*)-ona

$C_{27}H_{45}N_3O_6$



elotuzumabum #

elotuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* SLAM family member 7 (SLAM7, CD2 subset 1, CS1, CD2-like receptor-activating cytotoxic cells, CRACC, 19A24, CD319), humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV3-74*01 (81.60%) -IGHJ2*01, R120>Q) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-27*01 (84.20%) -IGKJ2*01, L124>V) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (228-228'':231-231'')-bisdisulfide dimer

elotuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* membre 7 de la famille SLAM (SLAM7, CD2 subset 1, CS1, CD2-like receptor-activating cytotoxic cells, CRACC, 19A24, CD319), anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV3-74*01 (81.60%) -IGHJ2*01, R120>Q) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-27*01 (84.20%) IGKJ2*01, L124>V) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure

elotuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* miembro 7 de la familia SLAM (conocido como: SLAM7, CD2 subset 1, CS1, CD2-like receptor-activating cytotoxic cells, CRACC, 19A24, CD319), anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV3-74*01 (81.60%) -IGHJ2*01, R120>Q) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-27*01 (84.20%) IGKJ2*01, L124>V) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero(228-228'':231-231'')-bisdisulfuro

$C_{6476}H_{9982}N_{1714}O_{2016}S_{42}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFDFS RYWMSWVRQA PGKGLEWIGE   50
INPDSSTINY APSLKDKFII SRDNAKNSLY LQMNSLRAED TAVYYCARPD  100
GNYWYFDVWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD  150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY  200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK  250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS  300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV  350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL  400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK   449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVG IAVAWYQQKP GKVPKLLIYW   50
ASTRHTGVPD RFSGSGSGTD FTLTISSLQP EDVATYYCQQ YSSYPYTFGQ  100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    146-202   263-323   369-427
         22''-96''  146''-202''  263''-323''  369''-427''
Intra-L  23'-88'   134'-194'
         23'''-88'''  134'''-194'''
Inter-H-L  222-214'  222''-214'''
Inter-H-H  228-228''  231-231''
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299''

farletuzumabum #

farletuzumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* folate receptor 1 (FOLR1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV3-30*03 (82.70%) -(IGHD)-IGHJ5*01, L123>P) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-217')-disulfide with kappa light chain (1'-217') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (80.20%) -IGKJ2*01, L124>V) [7.3.11] (1'-110') -*Homo sapiens* IGKC*01 (111'-217')]; (228-228":231-231")-bisdisulfide dimer

farletuzumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* réceptor 1 du folate (FOLR1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV3-30*03 (82.70%) -(IGHD)-IGHJ5*01, L123>P) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-217')-disulfure avec la chaîne légère kappa (1'-217') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (80.20%) -IGKJ2*01, L124>V) [7.3.11] (1'-110') -*Homo sapiens* IGKC*01 (111'-217')]; dimère (228-228":231-231")-bisdisulfure

farletuzumab — inmunoglobulina G1-kappa, anti-[receptor 1 de folato de *Homo sapiens* (conocido como: FOLR1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV3-30*03 (82.70%) -(IGHD)-IGHJ5*01, L123>P) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-217')-disulfuro con la cadena ligera kappa (1'-217') [V-KAPPA humanizada (*Homo sapiens* IGKV1-33*01 (80.20%) -IGKJ2*01, L124>V) [7.3.11] (1'-110') -*Homo sapiens* IGKC*01 (111'-217')]; dimero (228-228":231-231")-bisdisulfuro

$C_{6466}H_{9928}N_{1716}O_{2020}S_{42}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG VVQPGRSLRL SCSASGFTFS GYGLSWVRQA PGKGLEWVAM   50
ISSGGSYTYY ADSVKGRFAI SRDNAKNTLF LQMDSLRPED TGVYFCARHG  100
DDPAWFAYWG QGTPVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD  150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY  200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK  250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS  300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV  350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL  400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK   449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSS LSASVGDRVT ITCSVSSSIS SNNLHWYQQK PGKAPKPWIY   50
GTSNLASGVP SRFSGSGSGT DYTFTISSLQ PEDIATYYCQ QWSSYPYMYT  100
FGQGTKVEIK RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ  150
WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE KHKVYACEVT  200
HQGLSSPVTK SFNRGEC                                      217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L 23'-89' 137'-197'
23'"-89'" 137'"-197'"
Inter-H-L 222-217' 222"-217'"
Inter-H-H 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

fidaxomicinum

fidaxomicin

(3*E*,5*E*,8*S*,9*E*,11*S*,12*R*,13*E*,15*E*,18*S*)-3-{[(6-deoxy-4-*O*-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-*O*-methyl-β-D-mannopyranosyl)oxy]methyl}-12-{[6-deoxy-5-*C*-methyl-4-*O*-(2-methylpropanoyl)-β-D-*lyxo*-hexopyranosyl]oxy}-11-ethyl-8-hydroxy-18-[(1*R*)-1-hydroxyethyl]-9,13,15-trimethyloxacycloocta-3,5,9,13,15-pentaen-2-one


fidaxomicine

(3*E*,5*E*,8*S*,9*E*,11*S*,12*R*,13*E*,15*E*,18*S*)-3-({[6-déoxy-4-*O*-(3,5-dichloro-2-éthyl-4,6-dihydroxybenzoyl)-2-*O*-méthyl-β-D-mannopyranosyl]oxy}méthyl)-12-{[6-déoxy-5-*C*-méthyl-4-*O*-(2-méthylpropanoyl)-β-D-*lyxo*-hexopyranosyl]oxy}-11-éthyl-8-hydroxy-18-[(1*R*)-1-hydroxyéthyl]-9,13,15-triméthyloxacyclooctadéca-3,5,9,13,15-pentaén-2-one

fidaxomicina

3-{[(6-desoxi-4-*O*-(3,5-dicloro-2-etil-4,6-dihidroxibenzoil)-2-*O*-metil-β-D-manopiranosil)oxi]metil}-12-{[6-desoxi-5-*C*-metil-4-*O*-(2-metilpropanoil)-β-D-*lixo*-hexopiranosil]oxi}-11-etil-8-hidroxi-18-[(1*R*)-1-hidroxietil]-9,13,15-trimetiloxaciclooctа-3,5,9,13,15-pentaen-2-ona

$C_{52}H_{74}Cl_2O_{18}$



figitumumabum #

figitumumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* insulin-like growth factor 1 receptor (IGF-1R, CD221)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain (1-450) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG2*01, CH3 K130>del (126-450)], (139-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ2*04) [6.3.9] (1'-107') -IGKC*01] (108'-214'); (227-227'':228-228'':231-231'':234-234'')-tetradisulfide dimer

figitumumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* récepteur du facteur de croissance analogue à l'insuline 1 (IGF-1R, CD221)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma2 (1-450) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG2*01, CH3 K130>del (126-450)], (139-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ2*04) [6.3.9] (1'-107') -IGKC*01] (108'-214'); dimère (227-227'':228-228'':231-231'':234-234'')-tétradisulfure

figitumumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* receptor del factor de crecimiento insulínico tipo 1 de *Homo sapiens* (conocido como: IGF-1R, CD221)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma2 (1-450) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG2*01, CH3 K130>del (126-450)], (139-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ2*04) [6.3.9] (1'-107') -IGKC*01] (108'-214'); dímero (227-227'':228-228'':231-231'':234-234'')-tetradisulfuro

$C_{6450}H_{9924}N_{1732}O_{2018}S_{54}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCTASGFTFS SYAMNWVRQA PGKGLEWVSA   50
ISGSGGTTFY ADSVKGRFTI SRDNSRTTLY LQMNSLRAED TAVYYCAKDL  100
GWSDSYYYYY GMDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL  150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSN  200
FGTQTYTCNV DHKPSNTKVD KTVERKCCVE CPPCPAPPVA GPSVFLFPPK  250
PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF  300
NSTFRVVSVL TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP  350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP  400
MLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG  450
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQFPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKRLIYA   50
ASRLHRGVPS RFSGSGSGTE FTLTISSLQP EDFATYYCLQ HNSYPCSFGQ  100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    152-208    265-325    371-429
         22"-96"  152"-208"  265"-325"  371"-429"
Intra-L  23'-88'    134'-194'
         23'"-88'"  134'"-194'"
Inter-H-L  139-214'  139"-214'"
Inter-H-H  227-227"  228-228"  231-231"  234-234"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
301, 301"

fosbretabulinum

fosbretabulin

2-methoxy-5-[(1*Z*)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate


fosbrétabuline

dihydrogénophosphate de 2-méthoxy-5-[(1*Z*)-2-(3,4,5-triméthoxyphényl)éthényl]phényle

fosbretabulina

dihidròg enofosfato de 2-metoxi-5-[(1*Z*)-2-(3,4,5-trimetoxifenil)etenil]fenilo

$C_{18}H_{21}O_8P$




fostamatinibum

fostamatinib

[6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4*H*-pyrido[3,2-*b*][1,4]oxazin-4-yl]methyl dihydrogen phosphate

fostamatinib	dihydrogénophosphate de [6-({5-fluoro-2-[(3,4,5-triméthoxyphényl)amino]pyrimidin-4-yl}amino)-2,2-diméthyl-3-oxo-2,3-dihydro-4*H*-pyrido[3,2-*b*][1,4]oxazin-4-yl]méthyle
fostamatinib	dihidròg enofosfato de [6-({5-fluoro-2-[(3,4,5-trimetoxifenil)amino]pirimidin-4-il}amino)-2,2-dimetil-3-oxo-2,3-dihidro-4*H*-pirido[3,2-*b*][1,4]oxazin-4-il]metilo


$C_{23}H_{26}FN_6O_9P$



indeglitazarum

indeglitazar	3-[5-methoxy-1-(4-methoxybenzenesulfonyl)-1*H*-indol-3-yl]propanoic acid
indéglitazar	acide 3-{5-méthoxy-1-(4-méthoxybenzènesulfonyl)-1*H*-indol-3-yl}propanoïque
indeglitazar	ácido 3-[5-metoxi-1-(4-metoxibencenosulfonil)-1*H*-indol-3-il]propanoico

$C_{19}H_{19}NO_6S$




ingenoli mebutatum

ingenol mebutate	(1a*R*,2*S*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1*H*-2,8a-methanocyclopenta[*a*]cyclpropa[*e*][10]annulen-6-yl (2*Z*)-2-methylbut-2-enoate
mébutate d'ingénol	(2*Z*)-2-méthylbut-2-énoate de (1a*R*,2*S*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihydroxy-4-(hydroxyméthyl)-1,1,7,9-tétraméthyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1*H*-2,8a-méthanocyclopenta[*a*]cyclpropa[*e*][10]annulén-6-yle

mebutato de ingenol

(2*Z*)-2-metilbut-2-enoato de (1a*R*,2*S*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihidroxi-4-(hidroximetil)-1,1,7,9-tetrametil-11-oxo-1a,2,5,5a,6,9,10,10a-octahidro-1*H*-2,8a-metanociclopenta[*a*]ciclopropa[*e*][10]anulen-6-ilo

$C_{25}H_{34}O_6$



laninamivirum

laninamivir

(2*R*,3*R*,4*S*)-3-acetamido-2-[(1*R*,2*R*)-2,3-dihydroxy-1-methoxypropyl]-4-guanidino-3,4-dihydro-2*H*-pyran-6-carboxylic acid


laninamivir

acide (2*R*,3*R*,4*S*)-3-acétamido-2-[(1*R*,2*R*)-2,3-dihydroxy-1-méthoxypropyl]-4-guanidino-3,4-dihydro-2*H*-pyran-6-carboxylique

laninamivir

ácido (2*R*,3*R*,4*S*)-3-acetamido-2-[(1*R*,2*R*)-2,3-dihidroxi-1-metoxipropil]-4-guanidino-3,4-dihidro-2*H*-piran-6-carboxílico

$C_{13}H_{22}N_4O_7$



lesogaberanum

lesogaberan

(2*R*)-3-amino-2-fluoropropylphosphinic acid


lésogabéran

acide [(2*R*)-3-amino-2-fluoropropyl]phosphinique

lesogaberán

ácido (2*R*)-3-amino-2-fluoropropilfosfínico

$C_3H_9FNO_2P$



limiglidolum


limiglidole

2-(2,3-dihydro-9*H*-imidazo[1,2-*a*]benzimidazol-9-yl)-*N*,*N*-dimethylethanamine

limiglidole — 2-(2,3-dihydro-9*H*-imidazo[1,2-*a*]benzimidazol-9-yl)-*N*,*N*-diéthyléthanamine

limiglidol — 2-(2,3-dihidro-9*H*-imidazo[1,2-*a*]benzoimidazol-9-il)-*N*,*N*-dimetiletanamina

$C_{15}H_{22}N_4$




lotilibcinum

lotilibcin — 3-{(3*S*,6*R*,9*R*,12*R*,15*S*,18*R*,21*S*,24*R*,30*S*,33*R*,36*S*,40*R*)-33-[(1*R*)-2-amino-1-hydroxy-2-oxoethyl]-12-(2-amino-2-oxoethyl)-6,18-bis(3-aminopropyl)-24-benzyl-30,36-bis(hydroxymethyl)-9-(1*H*-indol-3-ylmethyl)-4,25-dimethyl-40-(4-methylpentyl)-21-(2-methylpropyl)-3-(propan-2-yl)-2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxo-1-oxa-4,7,10,13,16,19,22,25,28,31,34,37-dodecaazatetracontan-15-yl}propanoic acid

lotilibcine — acide 3-{(3*S*,6*R*,9*R*,12*R*,15*S*,18*R*,21*S*,24*R*,30*S*,33*R*,36*S*,40*R*)-33-[(1*R*)-2-amino-1-hydroxy-2-oxoéthyl]-12-(2-amino-2-oxoéthyl)-6,18-bis(3-aminopropyl)-24-benzyl-30,36-bis(hydroxyméthyl)-9-(1*H*-indol-3-ylméthyl)-4,25-diméthyl-40-(4-méthylpentyl)-21-(2-méthylpropyl)-3-(propan-2-yl)-2,5,8,11,14,17,20,23,26,29,32,35,38-tridécaoxo-1-oxa-4,7,10,13,16,19,22,25,28,31,34,37-dodécaazatétracontan-15-yl}propanoïque

lotilibcina — ácido 3-{(3*S*,6*R*,9*R*,12*R*,15*S*,18*R*,21*S*,24*R*,30*S*,33*R*,36*S*,40*R*)-33-[(1*R*)-2-amino-1-hidroxi-2-oxoetil]-12-(2-amino-2- oxoetil)-6,18-bis(3-aminopropil)-24-bencil-30,36-bis(hidroximetil)-9-(1*H*-indol-3-ilmetil)-4,25-dimetil-40-(4-metilpentil)-21-(2-metilpropil)-3-(propan-2-il)-2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxo-1-oxa-4,7,10,13,16,19,22,25,28,31,34,37-dodecaazatetracontan-15-il}propanoico

$C_{73}H_{111}N_{17}O_{21}$




macimorelinum

macimorelin — N^2-(2-amino-2-methylpropanoyl-N^1-[(1*R*)-1-formamido-2-(1*H*-indol-3-yl)ethyl]-D-tryptophanamide

macimoréline — N^2-(2-amino-2-méthylpropanoyl-N^1-[(1*R*)-1-formamido-2-(1*H*-indol-3-yl)éthyl]-D-tryptophanamide

macimorelina — N^2-(2-amino-2-metilpropanoil-N^1-[(1*R*)-1-formamido-2-(1*H*-indol-3-il)etil]-D-triptofanamide

$C_{26}H_{30}N_6O_3$




namitecanum

namitecan — (4*S*)-11-{(*E*)-[(2-aminoethoxy)imino]methyl}-4-ethyl-4-hydroxy-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-3,14(4*H*)-dione

namitécan — (4*S*)-11-{(*E*)-[(2-aminoéthoxy)imino]méthyl}-4-éthyl-4-hydroxy-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléine-3,14(4*H*)-dione

namitecán — (4*S*)-11-{(*E*)-[(2-aminoetoxi)imino]metil}-4-etil-4-hidroxi-1,12-dihidro-14*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolina-3,14(4*H*)-diona

$C_{23}H_{22}N_4O_5$



necitumumabum #

necitumumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* epidermal growth factor receptor (EGFR, ERBB1, HER1)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV4-30-4*01 (96.00%) -(IGHD)-IGHJ4*01) [10.7.13] (1-121) -IGHG1*03, CH1 F5>L (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (93.70%) -IGKJ4*01, V124>A) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (230-230'':233-233'')-bisdisulfide dimer

necitumumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* récepteur du facteur de croissance épidermique (EGFR, ERBB1, HER1)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV4-30-4*01 (96.00%) -(IGHD)-IGHJ4*01) [10.7.13] (1-121) -IGHG1*03, CH1 F5>L (122-451)], (224-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (93.70%) -IGKJ4*01, V124>A) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (230-230":233-233")-bisdisulfure

necitumumab

inmunoglobulina G1-kappa, anti-[receptor del factor de crecimiento epidérmico de *Homo sapiens* (conocido como: EGFR, ERBB1, HER1)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV4-30-4*01 (96.00%) -(IGHD)-IGHJ4*01) [10.7.13] (1-121) -IGHG1*03, CH1 F5>L (122-451)], (224-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (93.70%) -IGKJ4*01, V124>A) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (230-230":233-233")-bisdisulfuro

$C_{6436}H_{9958}N_{1702}O_{2020}S_{42}$

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGDYYWSWIR QPPGKGLEWI   50
GYIYYSGSTD YNPSLKSRVT MSVDTSKNQF SLKVNSVTAA DTAVYYCARV  100
SIFGVGTFDY WGQGTLVTVS SASTKGPSVL PLAPSSKSTS GGTAALGCLV  150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ  200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK  250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY  300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP  350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP  400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG  450
K                                                        451
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD   50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCHQ YGSTPLTFGG  100
GTKAEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-97    148-204    265-325    371-429
         22"-97"  148"-204"  265"-325"  371"-429"
Intra-L  23'-88'   134'-194'
         23'"-88'" 134'"-194'"
Inter-H-L  224-214'  224"-214'"
Inter-H-H  230-230"  233-233"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
301, 301"

oportuzumabum monatoxum #
oportuzumab monatox

immunoglobulin scFv fusion protein, anti-[*Homo sapiens* tumor-associated calcium signal transducer 1 (TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, epithelial cell adhesion molecule Ep-CAM, KSA, KS1/4 antigen, M4S1, tumor antigen 17-1A, CD326)] humanized monoclonal antibody scFv fused with *Pseudomonas aeruginosa* exotoxin A; hexahistidyl -humanized scFv [V-KAPPA (*Homo sapiens* IGKV1-39*01 (78%)- IGKJ1*01, I126>L) [11.3.9] (7-118) -26-mer linker -VH (*Homo sapiens* IGHV7-4-1*02 -(IGHD)-IGHJ4*01, V124>L) [8.8.9] (145-260)] -20-mer linker -*Pseudomonas aeruginosa* exotoxin A (ETA) [277-633 precursor fragment, containing domain II (281-393) with furin proteolytic cleavage site (302-313), domain Ib (394-433), domain III (434-637)] (281-637) -hexahistidyl-lysyl-aspartyl-glutamyl-leucyl

oportuzumab monatox	immunoglobuline scFv protéine de fusion, anti-[*Homo sapiens* transducteur 1 du signal calcium associé aux tumeurs (TACSTD1, protéine 2 associée aux tumeurs gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2, molécule d'adhésion des cellules épithéliales Ep-CAM, KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, CD326)] anticorps monoclonal humanisé scFv fusionné avec l'exotoxine A de *Pseudomonas aeruginosa*; hexahistidyl -scFv humanisé [V-KAPPA (*Homo sapiens* IGKV1-39*01 (78%)- IGKJ1*01, I126>L) [11.3.9] (7-118) -linker 26-mer -VH (*Homo sapiens* IGHV7-4-1*02 -(IGHD)- IGHJ4*01, V124>L) [8.8.9] (145-260)] -linker 20-mer -*Pseudomonas aeruginosa* exotoxine A (ETA) [fragment précurseur 277-633, comprenant domaine II (281-393) dont site de clivage protéolytique par la furine (302-313), domaine Ib (394-433), domaine III (434-637)] (281-637) - hexahistidyl-lysyl-aspartyl-glutamyl-leucyl
oportuzumab monatox	inmunoglobulina scFv proteína de fusión, anti-[*Homo sapiens* transductor 1 de la señal de calcio asociado a los tumores (TACSTD1, proteína 2 asociada a los tumores gastrointestinales, GA733-2, glicoproteína epitelial 2, EGP-2, molécula de adhesión de las células epiteliales Ep-CAM, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-1A, CD326)] anticuerpo monoclonal humanizado scFv fusionado con la exotoxina A de *Pseudomonas aeruginosa*; hexahistidil -scFv humanizado [V-KAPPA (*Homo sapiens* IGKV 1-39*01 (78%)- IGKJ1*01, I126>L) [11.3.9] (7-118) -linker 26-mer -VH (*Homo sapiens* IGHV7-4-1*02 -(IGHD)- IGHJ4*01, V124>L) [8.8.9] (145-260)] -linker 20-mer -*Pseudomonas aeruginosa* exotoxina A (ETA) [fragmento precursor 277-633, que comprende el dominio II (281-393) con el sitio de ruptura proteolítica por furina (302-313), dominio Ib (394-433), dominio III (434-637)] (281-637) - hexahistidil-lisil-aspartil-glutamil-leucil

$C_{3072}H_{4723}N_{877}O_{952}S_{12}$

scFv fusion protein / scFv protéine de fusion / scFv proteína de fusión

```
HHHHHHDIQM TQSPSSLSAS VGDRVTITCR STKSLLHSNG ITYLYWYQQK  50
PGKAPKLLIY QMSNLASGVP SRFSSSGSGT DFTLTISSLQ PEDFATYYCA 100
QNLEIPRTFG QGTKVELKRA TPSHNSHQVP SAGGPTANSG TSGSEVQLVQ 150
SGPGLVQPGG SVRISCAASG YTFTNYGMNW VKQAPGKGLE WMGWINTYTG 200
ESTYADSFKG RFTFSLDTSA SAAYLQINSL RAEDTAVYYC ARFAIKGDYW 250
GQGTLLTVSS EFGGAPEFPK PSTPPGSSGL EGGSLAALTA HQACHLPLET 300
FTRHRQPRGW EQLEQCGYPV QRLVALYLAA RLSWNQVDQV IRNALASPGS 350
GGDLGEAIRE QPEQARLALT LAAAESERFV RQGTGNDEAG AASADVVSLT 400
CPVAAGECAG PADSGDALLE RNYPTGAEFL GDGGDVSFST RGTQNWTVER 450
LLQAHRQLEE RGYVFVGYHG TFLEAAQSIV FGGVRARSQD LDAIWRGFYI 500
AGDPALAYGY AQDQEPDARG RIRNGALLRV YVPRSSLPGF YRTGLTLAAP 550
EAAGEVERLI GHPLPLRLDA ITGPEEEGGR LETILGWPLA ERTVVIPSAI 600
PTDPRNVGGD LDPSSIPDKE QAISALPDYA SQPGKPPHHH HHHKDEL    647
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
29-99 166-240 294-316 401-408

N-glycosylation site / Site de N-glycosylation / Posición de N-glicosilación
445

panobacumabum #

panobacumab

immunoglobulin M-kappa [*Pseudomonas aeruginosa* serotype IATS O11], *Homo sapiens* monoclonal antibody with a *Mus musculus* J chain;
mu heavy chain (1-569) [*Homo sapiens* VH (IGHV3-74*01 (92.90%) -(IGHD)-IGHJ3*01) [8.7.10] (1-116) -IGHM*03 (117-569)], (130-219')-disulfide with kappa light chain (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-30*01 (100%) -IGKJ4*01) [11.3.9] (1'-112') -IGKC*01 (113'-219'); (330-330")-monodisulfide dimer; (407-407":568-568")-octadisulfide between 5 dimers (a-e) to form a pentamer; pentamer (407"a-15"":568e-69"")-bisdisulfide with *Mus musculus* J chain (1""-138"")

panobacumab

immunoglobuline M-kappa [*Pseudomonas aeruginosa* sérotype IATS O11], *Homo sapiens* anticorps monoclonal avec la chaîne J de *Mus musculus*;
chaîne lourde mu (1-569) [*Homo sapiens* VH (IGHV3-74*01(92.90%) -(IGHD)-IGHJ3*01) [8.7.10] (1-116) -IGHM*03 (117-569)], (130-219')-disulfure avec la chaîne légère kappa (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-30*01 (100%) -IGKJ4*01) [11.3.9] (1'-112') -IGKC*01 (113'-219'); dimère (330-330")-monodisulfure; pentamère fait de 5 dimères (407-407":568-568")-octadisulfure; pentamère (407"a-15"":568e-69"")-bisdisulfure avec la chaîne J de *Mus musculus* (1""-138"")

panobacumab

inmunoglobulina M-kappa [*Pseudomonas aeruginosa* serotipo IATS O11], anticuerpo monoclonal de *Homo sapiens* con una cadena J de *Mus musculus* ;
cadena pesada mu (1-569) [*Homo sapiens* VH (IGHV3-74*01(92.90%) -(IGHD)-IGHJ3*01) [8.7.10] (1-116) -IGHM*03 (117-569)], (130-219')-disulfuro con la cadena ligera kappa (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-30*01 (100%) -IGKJ4*01) [11.3.9] (1'-112') -IGKC*01 (113'-219']; dímero (330-330")-monodisulfuro; pentámero compuesto de 5 dímeros (407-407":568-568")-octadisulfuro; pentámero (407"a-15"":568e-69"")-bisdisulfuro con la cadena J de *Mus musculus* (1""-138"")

$C_{38714}H_{60189}N_{10637}O_{12187}S_{322}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EEQVVESGGG FVQPGGSLRL SCAASGFTFS PYWMHWVRQA PGKGLVWVSR  50
INSDGSTYYA DSVKGRFTIS RDNARNTLYL QMNSLRAEDT AVYYCARDRY 100
YGPEMWGQGT MVTVSSGSAS APTLFPLVSC ENSPSDTSSV AVGCLAQDFL 150
PDSITFSWKY KNNSDISSTR GFPSVLRGGK YAATSQVLLP SKDVMQGTDE 200
HVVCKVQHPN GNKEKNVPLP VIAELPPKVS VFVPPRDGFF GNPRKSKLIC 250
QATGFSPRQI QVSWLREGKQ VGSGVTTDQV QAEAKESGPT TYKVTSTLTI 300
KESDWLSQSM FTCRVDHRGL TFQQNASSMC VPDQDTAIRV FAIPPSFASI 350
FLTKSTKLTC LVTDLTTYDS VTISWTRQNG EAVKTHTNIS ESHPNATFSA 400
VGEASICEDD WNSGERFTCT VTHTDLPSPL KQTISRPKGV ALHRPDVYLL 450
PPAREQLNLR ESATITCLVT GFSPADVFVQ WMQRGQPLSP EKYVTSAPMP 500
EPQAPGRYFA HSILTVSEEE WNTGETYTCV VAHEALPNRV TERTVDKSTG 550
KPTLYNVSLV MSDTAGTCY                                  569
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCRSSQSLV YSDGNTYLNW FQQRPGQSPR  50
RLIYKVSNRD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCMQGTHWP 100
LTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                  219
```

J chain / Chaîne J / Cadena J

```
GDDEATILAD NKCMCTRVTS RIIPSTEDPN EDIVERNIRI VVPLNNRENI  50
SDPTSPLRRN FVYHLSDVCK KCDPVEVELE DQVVTATQSN ICNEDDGVPE 100
TCYMYDRNKC YTTMVPLRYH GETKMVQAAL TPDSCYPD              138
```


Disulfide bridges location / Position des ponts disulfure /
Posiciones de los puentes disulfuro Intra chain
-IG monomer
Intra-H 22-95 144-204 250-313 360-419 467-529
22"-95" 144"-204" 250"-313" 360"-419" 467"-529"
Intra-L 23'-93' 139'-199' 23'"-93'" 139'"-199'"
Inter-H-L 130-219' 130"-219'"
Inter-H-H 330-330"
-J chain and pentamer
Intra-J 13'"-102'" 72'"-92'"" 110'"-135'""
Inter-H-H 407a-407"b 407b-407"c 407c-407"d 407d-407"e
568a-568"b 568b-568"c 568c-568"d 568d-568"e
Inter-H-J 407"a-15"" 568e-69""

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
IG monomer : 162, 162", 325, 325", 388, 388", 395, 395", 556, 556"
J chain: 49""

pitolisantum

pitolisant	1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine
pitolisant	1-{3-[3-(4-chlorophényl)propoxy]propyl}pipéridine
pitolisant	1-{3-[3-(4-clorofenil)propoxi]propil}piperidina


$C_{17}H_{26}ClNO$



pozaniclinum

pozanicline	2-methyl-3-{[(2*S*)-pyrrolidin-2-yl]methoxy}pyridine
pozanicline	2-méthyl-3-{[(2S)-pyrrolidin-2-yl]méthoxy}pyridine
pozaniclina	2-metil-3-{[(2*S*)-pirrolidin-2-il]metoxi}piridina

$C_{11}H_{16}N_2O$



racotumomabum #

racotumomab	immunoglobulin G1-kappa, anti-idiotype anti-[anti-(*N*-glycolylneuraminic acid (NeuGc, NGNA)-gangliosides GM3) *Mus musculus* IgM-kappa monoclonal antibody P3], *Mus musculus* monoclonal antibody; gamma1 heavy chain (1-445) [*Mus musculus* VH (IGHV1S56*01 -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -IGHG1*01, CH1 E84.2>Q, *N*-glycosylation sites CH2 N84.4, CH3 N84.4 (122-445)], (223-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (1'-107') -IGKC1*01 (108'-214')]; (225-225'':228-228'':230-230'')-trisdisulfide dimer
racotumomab	immunoglobuline G1-kappa, anti-idiotype anti-[anti-(acide *N*-glycolylneuraminique (NeuGc, NGNA)-gangliosides GM3) anticorps monoclonal IgM-kappa murin P3], *Mus musculus* anticorps monoclonal; chaîne lourde gamma1 (1-445) [*Mus musculus* VH (IGHV1S56*01 -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -IGHG1*01, CH1 E84.2>Q, sites de *N*-glycosylation CH2 N84.4, CH3 N84.4 (122-445)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (1'-107') -IGKC1*01 (108'-214')]; dimère (225-225'':228-228'':230-230'')-trisdisulfure

racotumomab

inmunoglobulina G1-kappa, anti-idiotipo anti-[anti-(ácido *N*-glicolilneuramínico (NeuGc, NGNA)-gangliósidos GM3) anticuerpo monoclonal murino P3 IgM-kappa], anticuerpo monoclonal de *Mus musculus*;
cadena pesada gamma1 (1-445) [*Mus musculus* VH (IGHV1S56*01 -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -IGHG1*01, CH1 E84.2>Q, posiciones de *N*-glicosilación CH2 N84.4, CH3 N84.4 (122-445)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (1'-107') -IGKC1*01 (108'-214')]; dímero (225-225":228-228":230-230")-trisdisulfuro

$C_{6476}H_{9922}N_{1712}O_{2048}S_{50}$

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGAE LVKPGASVKL SCKASGYTFT SYDINWVRQR PEQGLEWIGW   50
IFPGDGSTKY NEKFKGKATL TTDKSSSTAY MQLSRLTSED SAVYFCARED  100
YYDNSYYFDY WGQGTTLTVS SAKTTPPSVY PLAPGSAAQT NSMVTLGCLV  150
KGYFPEPVTV TWNSGSLSSG VHTFPAVLQS DLYTLSSSVT VPSSPRPSET  200
VTCNVAHPAS STKVDKKIVP RDCGCKPCIC TVPEVSSVFI FPPKPKDVLT  250
ITLTPKVTCV VVDISKDDPE VQFSWFVDDV EVHTAQTQPR EEQFNSTFRS  300
VSELPIMHQD WLNGKEFKCR VNSAAFPAPI EKTISKTKGR PKAPQVYTIP  350
PPKEQMAKDK VSLTCMITDF FPEDITVEWQ WNGQPAENYK NTQPIMNTNG  400
SYFVYSKLNV QKSNWEAGNT FTCSVLHEGL HNHHTEKSLS HSPGK       445
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQTTSS LSASLGDRVT ISCRASQDIS NYLNWYQQKP DGTVKLLIYY   50
TSRLHSGVPS RFSGSGSGTD YSLTISNLEQ EDIATYFCQQ GNTLPWTFGG  100
GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI  150
DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT  200
STSPIVKSFN RNEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96    148-203    259-319    365-423
          22"-96"  148"-203"  259"-319"  365"-423"
Intra-L   23'-88'    134'-194'
          23'"-88'"  134'"-194'"
Inter-H-L   223-214'  223"-214'"
Inter-H-H   225-225"  228-228"  230-230"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
295, 295"

ramucirumabum #

ramucirumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* vascular endothelial growth factor receptor 2 (VEGFR2, KDR, kinase insert domain receptor, FLK1, CD309) extracellular domain], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-21*01(99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) - IGHG1*03, R120>K (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (85.30%) - IGKJ4*01, E125>D) [6.3.9] (1'-107') -IGKC*01, R1.4>G (108'-214')]; (225-225":228-228")-bisdisulfide dimer

ramucirumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* récepteur 2 du facteur de croissance endothélial vasculaire (VEGFR2, KDR, récepteur à domaine insert kinase, FLK1, CD309) domaine extracellulaire], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV3-21*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03, R120>K (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01, E125>D) [6.3.9] (1'-107') -IGKC*01, R1.4>G (108'-214')]; dimère (225-225":228-228")-bisdisulfure

ramucirumab

inmunoglobulina G1-kappa, anti-[receptor 2 del factor de crecimiento endotelial vascular de *Homo sapiens* (conocido como: VEGFR2, KDR, receptor con dominio inserto-kinasa, FLK1, CD309) dominio extracelular], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV3-21*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03, R120>K (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01, E125>D) [6.3.9] (1'-107') -IGKC*01, R1.4>G (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro

$C_{6374}H_{9896}N_{1692}O_{1996}S_{46}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGGG LVKPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSS  50
ISSSSSYIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARVT 100
DAFDIWGQGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS VSASIGDRVT ITCRASQGID NWLGWYQQKP GKAPKLLIYD  50
ASNLDTGVPS RFSGSGSGTY FTLTISSLQA EDFAVYFCQQ AKAFPPTFGG 100
GTKVDIKGTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    143-199    260-320    366-424
         22"-96"  143"-199"  260"-320"  366"-424"
Intra-L  23'-88'   134'-194'
         23'"-88'" 134'"-194'"
Inter-H-L  219-214'  219"-214'"
Inter-H-H  225-225"  228-228"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
296, 296"

regorafenibum

regorafenib

4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-*N*-methylpyridine-2-carboxamide


régorafénib

4-[4-({[4-chloro-3-(trifluorométhyl)phényl]carbamoyl}amino)-3-fluorophénoxy]-*N*-méthylpyridine-2-carboxamide

regorafenib

4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-*N*-metilpiridina-2-carboxamida

$C_{21}H_{15}ClF_4N_4O_3$



riferminogenum pecaplasmidum #

riferminogene pecaplasmid

plasmid DNA vector with a conditional origin of replication (pCOR) expressing a hybrid protein consisting of a secretion signal peptide from human fibroblast interferon ß fused to the *N*-terminus of a truncated form of the human fibroblast growth factor-1 (FGF-1) from amino acid 21 to 154 under the control of a cytomegalovirus promoter

riferminogène pécaplasmide	vecteur constitué d'ADN plasmidique avec origine de réplication conditionnelle (pCOR), exprimant une protéine hybride constituée d'un peptide signal de sécrétion de l'interféron ß de fibroblaste humain, fusionnée à l'extrémité *N*-terminale de la forme tronquée du facteur de croissance des fibroblastes-1 (FGF-1) de l'acide aminé 21 au 154, sous le contrôle d'un promoteur de cytomégalovirus
riferminogén pecaplásmido	vector de DNA plasmídico con un origen de replicación condicionado (pCOR) que expresa una proteína híbrida que consiste en el péptido señal de secreción del interferón ß de fibroblastos humanos, fusionado con la región amino terminal de una forma truncada del factor de crecimiento de fibroblastos humano-1 (FGF-1), desde el aminoácido 21 al 154, bajo el control de un promotor de citomegalovirus

robatumumabum #

robatumumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* insulin-like growth factor I receptor (IGF-1R, CD221)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-48*03 (87.80%) -(IGHD)-IGHJ6*01) [8.7.12] (1-118) -IGHG1*01 (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (83.30%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01] (108'-214'); (227-227'':230-230'')-bisdisulfide dimer
robatumumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* récepteur du facteur de croissance analogue à l'insuline 1 (IGF-1R, CD221)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV3-48*03 (87.80%) -(IGHD)-IGHJ6*01) [8.7.12] (1-118) -IGHG1*01 (119-448)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (83.30%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01] (108'-214'); dimère (227-227'':230-230'')-bisdisulfure
robatumumab	inmunoglobulina G1-kappa, anti-[receptor del factor de crecimiento insulínico tipo 1 de *Homo sapiens* (IGF-1R, CD221)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV3-48*03 (87.80%) -(IGHD)-IGHJ6*01) [8.7.12] (1-118) -IGHG1*01 (119-448)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (83.30%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01] (108'-214'); dímero (227-227'':230-230'')-bisdisulfuro

$C_{6418}H_{9960}N_{1732}O_{1992}S_{42}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGGG LVKPGGSLRL SCAASGFTFS SFAMHWVRQA PGKGLEWISV  50
IDTRGATYYA DSVKGRFTIS RDNAKNSLYL QMNSLRAEDT AVYYCARLGN 100
FYYGMDVWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSVSPGERAT LSCRASQSIG SSLHWYQQKP GQAPRLLIKY  50
ASQSLSGIPD RFSGSGSGTD FTLTISRLEP EDFAVYYCHQ SSRLPHTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-95 145-201 262-322 368-426
22"-95" 145"-201" 262"-322" 368"-426"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 221-214' 221"-214'"
Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298"


selumetinibum

selumetinib — 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-*N*-(2-hydroxyethoxy)-1-methyl-1*H*-benzimidazole-6-carboxamide

sélumétinib — 5-[(4-bromo-2-chlorophényl)amino]-4-fluoro-*N*-(2-hydroxyéthoxy)-1-méthyl-1*H*-benzimidazole-6-carboxamide

selumetinib — 5-[(4-bromo-2-clorofenil)amino]-4-fluoro-*N*-(2-hidroxietoxi)-1-metil-1*H*-benzoimidazol-6-carboxamida

$C_{17}H_{15}BrClFN_4O_3$




serlopitantum

serlopitant — 3-[(3a*R*,4*R*,5*S*,7a*S*)-5-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-2*H*-isoindol-2-yl]cyclopent-2-en-1-one

serlopitant — 3-[(3a*R*,4*R*,5*S*,7a*S*)-5-{(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy}-4-(4-fluorophényl)octahydro-2*H*-isoindol-2-yl]cyclopent-2-énone

serlopitant — 3-[(3a*R*,4*R*,5*S*,7a*S*)-5-{(1*R*)-1-[3,5-bis(trifluorometil)fenil]etoxi}-4-(4-fluorofenil)octahidro-2*H*-isoindol-2-il]ciclopent-2-en-1-ona

$C_{29}H_{28}F_7NO_2$



siltuximabum #

siltuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* interleukin 6 (IL6, IL-6)], chimeric monoclonal antibody;
gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV5-9-4*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-213')-disulfide with kappa light chain (1'-213') [*Mus musculus* V-KAPPA (IGKV4-55*01 –IGKJ2*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; (228-228":231-231")-bisdisulfide dimer

siltuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* interleukine 6 (IL6, IL-6)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV5-9-4*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-213')-disulfure avec la chaîne légère kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-55*01 -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (228-228":231-231")-bisdisulfure

siltuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* interleukina 6 (IL6, IL-6)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV5-9-4*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-213')-disulfuro con la cadena ligera kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-55*01 -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (228-228":231-231")-bisdisulfuro

$C_{6450}H_{9932}N_{1688}O_{2016}S_{50}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGK LLKPGGSLKL SCAASGFTFS SFAMSWFRQS PEKRLEWVAE   50
ISSGGSYTYY PDTVTGRFTI SRDNAKNTLY LEMSSLRSED TAMYYCARGL  100
WGYYALDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD  150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY  200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK  250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS  300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV  350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL  400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK   449
```

Light chain / Chaîne légère / Cadena ligera

```
QIVLIQSPAI MSASPGEKVT MTCSASSSVS YMYWYQQKPG SSPRLLIYDT   50
SNLASGVPVR FSGSGSGTSY SLTISRMEAE DAATYYCQQW SGYPYTFGGG  100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD  150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL  200
SSPVTKSFNR GEC                                          213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro


```
Intra-H  22-96    146-202    263-323    369-427
         22"-96"  146"-202"  263"-323"  369"-427"
Intra-L  23'-87'    133'-193'
         23'"-87'"  133'"-193'"
Inter-H-L  222-213'  222"-213'"
Inter-H-H  228-228"  231-231"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

sobetiromum

sobetirome	(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)acetic acid
sobétirome	acide (4-{[4-hydroxy-3-(1-méthyléthyl)phényl]méthyl}-3,5-diméthylphénoxy)acétique
sobetiroma	ácido (4-{[4-hidroxi-3-(propan-2-il)fenil]metil}-3,5-dimetilfenoxi)acético


$C_{20}H_{24}O_4$



sofiniclinum

sofinicline	(1*S*,5*S*)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane
sofinicline	(-)-(1*S*,5*S*)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane
sofiniclina	(1*S*,5*S*)-3-(5,6-dicloropiridin-3-il)-3,6-diazabiciclo[3.2.0]heptano

$C_{10}H_{11}Cl_2N_3$



solanezumabum #

solanezumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* amyloid-beta (Abeta) peptide soluble monomer], humanized monoclonal antibody; gamma1 heavy chain [humanized VH (*Homo sapiens* IGHV3-23*04 (87.60%) -(IGHD)-IGHJ4*01) [8.8.5] (1-112) -*Homo sapiens* IGHG1*01, CH3 K130>del (113-441)], (215-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (221-221":224-224")-bisdisulfide dimer
solanezumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* amyloïde-bêta (Abeta) peptide monomère soluble], anticorps monoclonal humanisé; chaîne lourde gamma1 [VH humanisé (*Homo sapiens* IGHV3-23*04 (87.60%) -(IGHD)-IGHJ4*01) [8.8.5] (1-112) -*Homo sapiens* IGHG1*01, CH3 K130>del (113-441)], (215-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (221-221":224-224")-bisdisulfure

solanezumab

inmunoglobulina G1-kappa, anti-[péptido amiloide-beta (Abeta) monomèrico soluble de *Homo sapiens*], anticuerpo monoclonal humanizado;
cadena pesada gamma1 [VH humanizada (*Homo sapiens* IGHV3-23*04 (87.60%) -(IGHD)-IGHJ4*01) [8.8.5] (1-112) -*Homo sapiens* IGHG1*01, CH3 K130>del (113-441)], (215-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (221-221":224-224")-bisdisulfuro

$C_{6396}H_{9922}N_{1712}O_{1996}S_{42}$

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYSMSWVRQA PGKGLELVAQ  50
INSVGNSTYY PDTVKGRFTI SRDNAKNTLY LQMNSLRAED TAVYYCASGD 100
YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT 150
VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT QTYICNVNHK 200
PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR 350
DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G          441
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCRSSQSLI YSDGNAYLHW FLQKPGQSPR  50
LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHVP 100
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    139-195    256-316    362-420
         22"-96"  139"-195"  256"-316"  362"-420"
Intra-L  23'-93'   139'-199'
         23'"-93'"  139'"-199'"
Inter-H-L  215-219'  215"-219'"
Inter-H-H  221-221"  224-224"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
292, 292"

taberminogenum vadenovecum #

taberminogene vadenovec

recombinant E1a and E3 deleted (non-replicating), adenovirus (serotype 5) containing a vascular endothelial growth factor – D (VEGF-D) gene driven by a CMV promoter

taberminogène vadénovec

adénovirus (sérotype 5) recombinant (non répliquant), régions E1a et E3 supprimées, contenant un gène du facteur de croissance de l'endothélium vasculaire – D (VEGF-D), sous contrôle d'un promoteur de cytomégalovirus (CMV)

taberminogén vadenovec

adenovirus recombinante (serotipo 5) (no replicativo) con deleción de los genes E1a y E3, que contiene el factor de crecimiento endotelial vascular – D (VEGF-D) bajo el control de un promotor de citomegalovirus (CMV)

tarafenacinum

tarafenacin

(3*R*)-1-azabicyclo[2.2.2]octan-3-yl (3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]carbamate


tarafénacine

(3-fluorophényl)[(3,4,5-trifluorophényl)méthyl]carbamate de (3*R*)-1-azabicyclo[2.2.2]oct-3-yle

tarafenacina

(3-fluorofenil)[(3,4,5-trifluorofenil)metil]carbamato de (3*R*)-1-azabiciclo[2.2.2]octan-3-ilo


$C_{21}H_{20}F_4N_2O_2$



telcagepantum

telcagepant	*N*-[(3*R*,6*S*)-6-(2,3-diflurophenyl)-2-oxo-1-(2,2,2-trifluroethyl)azepan-3-yl]-4-{2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-1-yl}piperidine-1-carboxamide
telcagépant	*N*-[(3*R*,6*S*)-6-(2,3-difluorophényl)-2-oxo-1-(2,2,2-trifluoroéthyl)-azépan-3-yl]-4-(2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-1-yl)pipéridine-1-carboxamide
telcagepant	*N*-[(3*R*,6*S*)-6-(2,3-difluorofenil)-2-oxo-1-(2,2,2-trifluoroetil)azepan-3-il]-4-{2-oxo-2,3-dihidro-1*H*-imidazo[4,5-*b*]piridin-1-il}piperidina-1-carboxamida


$C_{26}H_{27}F_5N_6O_3$



tilivapramum

tilivapram	4-[4-(cyclopropylmethoxy)-5-methoxypyridine-2-carboxamido]-3,5-dichloropyridine 1-oxide
tilivapram	1-oxyde de 4-[4-(cyclopropylméthoxy)-5-méthoxypyridine-2-carboxamido]-3,5-dichloropyridine
tilivapram	1-óxido de 4-[4-(ciclopropilmetoxi)-5-metoxipiridina-2-carboxamido]-3,5-dicloropiridina

$C_{16}H_{15}Cl_2N_3O_4$




toceranibum

toceranib — 5-[(5*Z*)-(5-fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene)methyl]-2,4-dimethyl-*N*-[2-(pyrrolidin-1-yl)ethyl]-1*H*-pyrrole-3-carboxamide

tocéranib — 5-[(5*Z*)-(5-fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidène)méthyl]-2,4-diméthyl-*N*-[2-(pyrrolidin-1-yl)éthyl]-1*H*-pyrrole-3-carboxamide

toceranib — 5-[(5*Z*)-(5-fluoro-2-oxo-1,2-dihidro-3*H*-indol-3-ilideno)metil]-2,4-dimetil-*N*-[2-(pirrolidin-1-il)etil]-1*H*-pirrol-3-carboxamida

$C_{22}H_{25}FN_4O_2$




tozasertibum

tozasertib — *N*-[4-({4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1*H*-pyrazol-3-yl)amino]pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide

tozasertib — *N*-[4-({4-(4-méthylpipérazin-1-yl)-6-[(5-méthyl-1*H*-pyrazol-3-yl)amino]pyrimidin-2-yl}sulfanyl)phényl]cyclopropanecarboxamide

tozasertib — *N*-[4-({4-(4-metilpiperazin-1-il)-6-[(5-metil-1*H*-pirazol-3-il)amino]pirimidin-2-il}sulfanil)fenil]ciclopropanocarboxamida

$C_{23}H_{28}N_8OS$



vanutidum cridificarum #

vanutide cridificar — inactivated diphtheria toxin (carrier) covalently linked to human beta-amyloid protein 42 short fragments: pentadecakis[$N^{6\text{-Lys}}$-(sulfanylacetyl)]-[52-glutamic acid(G>E)]diphtheria toxin *Corynebacterium diphtheriae* thioether with human beta-amyloid protein 42-(1-7)-peptidylcysteine

vanutide cridificar — court fragment de la protéine 42 bêta-amyloïde liée de façon covalente à la toxine diphtérique inactivée (vecteur) : thioéthers entre la protéine 42 bêta-amyloïde humaine-(1-7)peptidylcystéine et la pentadécakis[$N^{6\text{-Lys}}$-(sulfanylacétyl)]-[52-acide glutamique(G>E)]toxine diphtérique *Corynebacterium diphtheriae*


vanutida cridificar

pequeño fragmento de la proteína 42 beta-amiloide unido covalentemente a la toxina diftérica inactivada (vector) : tioéteres entre la proteína 42 beta-amiloide humana-(1-7)peptidilcisteína y la pentadecakis[$N^{6\text{-Lys}}$-(sulfanilacetil)]-[52-ácido glutámico G>E)]toxina diftérica *Corynebacterium diphtheriae*

$C_{3215}H_{4916}N_{900}O_{1053}S_{27}$

```
GADDVVDSSK SFVMENFSSY HGTKPGYVDS IQKGIQKPKS GTQGNYDDDW 50
KEFYSTDNKY DAAGYSVDNE NPLSGKAGGV VKVTYPGLTK VLALKVDNAE 100
TIKKELGLSL TEPLMEQVGT EEFIKRFGDG ASRVVLSLPF AEGSSSVEYI 150
NNWEQAKALS VELEINFETR GKRGQDAMYE YMAQACAGNR VRRSVGSSLS 200
CINLDWDVIR DKTKTKIESL KEHGPIKNKM SESPNKTVSE EKAKQYLEEF 250
HQTALEHPEL SELKTVTGTN PVFAGANYAA WAVNVAQVID SETADNLEKT 300
TAALSILPGI GSVMGIADGA VHHNTEEIVA QSIALSSLMV AQAIPLVGEL 350
VDIGFAAYNF VESIINLFQV VHNSYNRPAY SPGHKTQPFL HDGYAVSWNT 400
VEDSIIRTGF QGESGHDIKI TAENTPLPIA GVLLPTIPGK LDVNKSKTHI 450
SVNGRKIRMR CRAIDGDVTF CRPKSPVYVG NGVHANLHVA FHRSSSEKIH 500
SNEISSDSIG VLGYQKTVDH TKVNSKLSLF FEIKS                 535
```

Modified residues / Résidus modifiés / Residuos modificados
K (-Lys-)
an average of 15 out of 39 lysines are modified
environ 15 des 39 lysines sont modifiées
aproximadamente 15 de las 39 lisinas están modificadas



Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
186-201 461-471

vedolizumabum #

vedolizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* alpha4beta7 integrin (lymphocyte Peyer's patch adhesion molecule 1, LPAM-1), humanized monoclonal antibody;
gamma1 heavy chain (1-451) [humanized VH (*Homo sapiens* IGHV1-3*01 (84.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, CH2 L1.2>A, G1>A (122-451)], (224-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-29*02 (84.00%) -IGKJ2*01, L124>V) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (230-230":233-233")-bisdisulfide dimer

védolizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* intégrine alpha4bêta7 (molécule 1 d'adhésion des lymphocytes des plaques de Peyer, LPAM-1), anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-451) [VH humanisé (*Homo sapiens* IGHV1-3*01 (84.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, CH2 L1.2>A, G1>A (122-451)] , (224-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-29*02 (84.00%) -IGKJ2*01, L124>V) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (230-230":233-233")-bisdisulfure

vedolizumab

inmunoglobulina G1-kappa, anti-[integrina alfa4beta7 de *Homo sapiens* (conocida como: molécula 1 de adhesión de los linfocitos de las placas de Peyer, LPAM-1), anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-451) [VH humanizado (*Homo sapiens* IGHV1-3*01 (84.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, CH2 L1.2>A, G1>A (122-451)] , (224-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2-29*02 (84.00%) -IGKJ2*01, L124>V) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (230-230":233-233")-bisdisulfuro

$C_{6528}H_{10072}N_{1732}O_{2042}S_{42}$

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKGSGYTFT SYWMHWVRQA PGQRLEWIGE  50
IDPSESNTNY NQKFKGRVTL TVDISASTAY MELSSLRSED TAVYYCARGG 100
YDGWDYAIDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELAG APSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTPGEPAS ISCRSSQSLA KSYGNTYLSW YLQKPGQSPQ  50
LLIYGISNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQGTHQP 100
YTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    148-204   265-325   371-429
         22"-96"  148"-204" 265"-325" 371"-429"
Intra-L  23'-93'   139'-199'
         23'"-93'" 139'"-199'"
Inter-H-L  224-219'  224"-219'"
Inter-H-H  230-230"  233-233"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

301, 301"

zicronapinum

zicronapine

4-[(1*R*,3*S*)-6-chloro-3-phenyl-2,3-dihydro-1*H*-inden-1-yl]-1,2,2-trimethylpiperazine


zicronapine

4-[(1*R*,3*S*)-6-chloro-3-phényl-2,3-dihydro-1*H*-indén-1-yl]-1,2,2-triméthylpipérazine

zicronapina

4-[(1*R*,3*S*)-6-cloro-3-fenil-2,3-dihidro-1*H*-inden-1-il]-1,2,2-trimetilpiperazina

$C_{22}H_{27}ClN_2$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Non Proprietary Names (Rec. INN): List 53
Dénominations communes internationales recommandées (DCI Rec.): Liste 53
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 53
(WHO Drug Information, Vol. 19, No. 1, 2005)

p. 83	*suprimáse*	*insértese*
	lenalidomide	lenalidomida

Recommended International Non Proprietary Names (Rec. INN): List 59
Dénominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 21, No. 2, 2007)

p. 45	*supprimer*	*insérer*
	bromure d'azixomère	bromure d'azoximère

Recommended International Non Proprietary Names (Rec. INN): List 61
Dénominations communes internationales recommandées (DCI Rec.): Liste 61
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 61
(WHO Drug Information, Vol. 23, No. 1, 2009)

p. 52 **bafetinibum**

bafetinib — *replace the chemical name and the structure by the following*


bafétinib — *remplacer le nom chimique et la structure par les suivants*

bafetinib — *sustitúyase el nombre químico y la fórmula desarrollada por los siguientes*

N-{3-[([4,5'-bipyrimidin]-2-yl)amino]-4-methylphenyl}-4-{[(3*S*)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide


N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-méthylphényl]-4-{[(3*S*)-3-(diméthylamino)pyrrolidin-1-yl]méthyl}-3-(trifluorométhyl)benzamide

N-{3-[([4,5'-bipirimidin]-2-il)amino]-4-metilfenil}-4-{[(3*S*)-3-(dimetilamino)pirrolidin-1-il]metil}-3-(trifluorometil)benzamida



p. 66 **levomilnacipranum**

levomilnacipran	*replace the structure by the following*
lévomilnacipran	*remplacer la structure par la suivante*
levomilnaciprán	*sustitúyase la fórmula desarrollada por la siguiente*



Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.